- Home
- ANL vs ASRT Comparison
ANL vs ASRT Comparison
Compare ANL & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANL
- ASRT
- Stock Information
- Founded
- ANL 2004
- ASRT 1995
- Country
- ANL Cayman Islands
- ASRT United States
- Employees
- ANL N/A
- ASRT N/A
- Industry
- ANL
- ASRT Biotechnology: Pharmaceutical Preparations
- Sector
- ANL
- ASRT Health Care
- Exchange
- ANL Nasdaq
- ASRT Nasdaq
- Market Cap
- ANL 56.0M
- ASRT 57.9M
- IPO Year
- ANL 2023
- ASRT 1997
- Fundamental
- Price
- ANL $1.45
- ASRT $0.71
- Analyst Decision
- ANL Hold
- ASRT Strong Buy
- Analyst Count
- ANL 1
- ASRT 1
- Target Price
- ANL N/A
- ASRT $3.50
- AVG Volume (30 Days)
- ANL 6.9K
- ASRT 236.4K
- Earning Date
- ANL 08-12-2025
- ASRT 08-11-2025
- Dividend Yield
- ANL N/A
- ASRT N/A
- EPS Growth
- ANL N/A
- ASRT N/A
- EPS
- ANL N/A
- ASRT N/A
- Revenue
- ANL N/A
- ASRT $119,001,000.00
- Revenue This Year
- ANL N/A
- ASRT N/A
- Revenue Next Year
- ANL N/A
- ASRT $11.91
- P/E Ratio
- ANL N/A
- ASRT N/A
- Revenue Growth
- ANL N/A
- ASRT N/A
- 52 Week Low
- ANL $1.10
- ASRT $0.51
- 52 Week High
- ANL $3.89
- ASRT $1.40
- Technical
- Relative Strength Index (RSI)
- ANL 44.72
- ASRT 53.99
- Support Level
- ANL $1.48
- ASRT $0.66
- Resistance Level
- ANL $1.55
- ASRT $0.79
- Average True Range (ATR)
- ANL 0.04
- ASRT 0.03
- MACD
- ANL -0.00
- ASRT -0.00
- Stochastic Oscillator
- ANL 25.00
- ASRT 40.38
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.